Medicine helps liver fat in transplant patients

Original Title

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

A medicine called saroglitazar was given to people who had liver transplants and had fatty liver. After 24 weeks, their liver fat went down on average. The medicine didn’t hurt their muscles and was generally safe.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Liver fat went down while belly fat went up — even though weight didn’t change.

It’s counterintuitive — people expect fat loss to be uniform or at least not redistribute to the belly. This suggests the drug may be shifting fat from the liver to the abdomen, which is unexpected.

Practical Takeaways

If you have fatty liver disease, especially after liver transplant, ask your doctor about saroglitazar — it may help reduce liver fat without harming muscle.

low confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.

32%
Lower QualityOverall Score

Publication

Journal

Liver Transplantation

Year

2023

Authors

M. Siddiqui, D. Parmar, Farheen S. Shaikh, M. Forsgren, S. Patel, A. Bui, Sherry L Boyett, V. Patel, A. Sanyal

12 citations
Analysis v1